
An expert discusses the personalized approach to treating ROS1-positive non-small cell lung cancer, emphasizing the preference for next-generation TKIs like talotrectinib and repotrectinib due to their CNS activity and efficacy against resistance mutations, particularly G2032R, while highlighting the importance of molecular profiling, avoiding immunotherapy, and considering clinical trials or chemotherapy in later-line settings.